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Aims Professional practice guidelines recommend that pacemaker recipients be followed regularly. However, the majority
of scheduled ambulatory visits is unproductive and imposes a heavy burden on the health-care system.
Methods
and results
The COMPAS randomized, multicentre, non-inferiority trial examined the safety of long-term remote monitoring of
pacemakers. Between December 2005 and January 2008, 538 patients were randomly assigned to remote monitoring
follow-up (active group) vs. standard care (control group). The primary objective was to conﬁrm that the proportion
of patients who experienced at least one major adverse event (MAE), including all-cause death and hospitalizations
for device-related or cardiovascular adverse events, was not .7% higher in the active than in the control group.
MAE-free survivals and quality of life were compared in both groups. The characteristics of the study groups
were similar. Over a follow-up of 18.3 months, 17.3% of patients in the active and 19.1% in the control group experi-
enced at least one MAE (P , 0.01 for non-inferiority). Hospitalizations for atrial arrhythmias (6 vs. 18) and strokes
(2 vs. 8) were fewer (P , 0.05), and the number of interim ambulatory visits was 56% lower (P , 0.001) in the active
than the control group. Changes in pacemaker programming or drug regimens were made in 62% of visits in the
active vs. 29% in the control group (P , 0.001). Quality of life remained unchanged in both groups.
Conclusion Remote monitoring was a safe alternative to conventional care and signiﬁcantly lowered the number of ambulatory
visits during long-term follow-up of permanently paced patients.
ClinicalTrials.gov identiﬁer: NCT00989326.
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Introduction
Professional practice guidelines recommend that pacemaker recipi-
ents be followed regularly.
1,2 These regular ofﬁce visits include
examinations of device function and patient clinical status, and
may prompt the reprogramming of the device or changes in medi-
cation regimens. The efﬁciency of this strategy is, however, ques-
tionable since, in the majority of scheduled visits, the device
programming or drug regimen is left unchanged.
3 To optimize
the follow-up of device recipients, systems have been developed,
which allow the automatic teletransmission of data stored in the
devices’ memories, including battery voltage, lead characteristics,
and arrhythmias. The data sent by a home transmitter allow the
remote surveillance of patients and eliminate unnecessary ambula-
tory visits. Clinical studies of these new systems have been con-
ducted mostly in recipients of cardioverter deﬁbrillators, and
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lished.
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The French randomized, multicentre ‘COMPArative follow-up
Schedule with home monitoring’ (COMPAS) trial was conducted
to evaluate the beneﬁts of remote monitoring after ﬁrst implant-
ation or replacement of dual chamber pacemakers and, speciﬁcally,
to determine whether remote monitoring could replace the stand-
ard long-term follow-up of patients with regard to the adverse
events related or unrelated to the implanted devices.
Methods
Primary study objective
The primary objective of this non-inferiority trial was to conﬁrm that
the proportion of patients who experienced at least one major adverse
event (MAE), including (i) death, (ii) hospitalization for complications
related to the pacing system, and (iii) hospitalization for an adverse car-
diovascular event, was not higher in the remote follow-up (active) than
in the standard care (control) group.
Secondary objectives
The secondary objectives of the trial were to (i) compare the inci-
dence of each MAE in both groups, (ii) measure the decrease in the
number of in-ofﬁce follow-ups conferred by remote monitoring,
(iii) retrospectively analyse the delay in the management of adverse
events in both study groups, (iv) compare the contributions of the
follow-ups in both groups, and (v) examine the effect of remote mon-
itoring on quality of life.
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Patient selection
Patients were eligible for inclusion in the COMPAS trial if (i) they had
undergone implantation of a PHILOS II DR-T DDD pacemaker (Bio-
tronik SE and Co. KG, Berlin, Germany) with an A/V bipolar lead,
for standard pacing indications, at least 1 month earlier,
1,2 and
(ii) were able to (a) comply with the study protocol and (b) sign an
informed consent. To optimize the safety of the trial and compliance
with the protocol, the patients were excluded if their spontaneous
ventricular rate was ,30 b.p.m.
Telecardiology system
Home Monitoring
w (Biotronik) is a system that automatically transmits
the data stored in implantable devices to the Biotronik service centre,
over a wireless global system for mobile communications network.
After an automatic analysis, messages are posted daily on a secure
Internet site accessible to the physician responsible for the patient’s
care. In case of clinical or technical anomaly (or both), the device
emits additional warning messages, which are immediately forwarded
by the service centre to the physician (Table 1).
Study protocol
COMPAS was a randomized, open-label, parallel-design trial, in which
43 French medical centres participated, including 30 public and 13
private institutions (see Supplementary material online, appendices).
The trial protocol, which complied with the declaration of Helsinki,
was reviewed and approved by the pertinent National Ethics Commit-
tees, and all patients granted their written, informed consent to partici-
pate. COMPAS was sponsored by Biotronik SE and Co. KG that
participated to the study design and data monitoring. Patients who
...............................................................................................................................................................................
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Table 1 Technical and clinical information transmitted daily, along with corresponding warnings in case of detected
anomaly
Daily transmission Associated warning messages (warning
level)
Device programming in both study
groups
Technical information DDD or DDDR mode
Battery status Elective replacement indicator (I)
Atrial lead impedance Atrial lead impedance ,200 or .3000 V (I) Automatic atrial lead test: ON
Ventricular lead impedance Ventricular lead impedance ,200 or .3000 V (I) Automatic ventricular lead test: ON
R-wave safety margin R-wave safety margin ,50% (I)
P-wave safety margin P-wave safety margin ,50% (I)
Ventricular capture threshold Autothreshold deactivated (I) Autothreshold: ON
Ventricular threshold .4.8 V (I)
Variations in ventricular threshold .1 V (II)
No transmission No transmission in last 14 days (I) Transmission at 3:00 a.m.
Clinical information
Mean ventricular rate/24 h
Number and duration of atrial arrhythmia Three consecutive episodes .18 h (I) Mode switch: ON
First episode since onset of follow-up (II)
Peak ventricular rate during mode switch IEGM recording for mode switch: ON
Daily peak ventricular rate IEGM recording for ventricular rate: ON
Duration of episode with fastest ventricular
rate
Ventricular rate .160 b.p.m.
Number of ventricular episodes More than eight consecutive PVC (II)
(I), warning level I prompting a mandatory interim follow-up; (II), warning level II prompting an optional interim follow-up; PVC, premature ventricular complex; IEGM, intracardiac
electrogram.
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assigned to an active vs. a control group at least 1 month after the
pacemaker implantation.
The patients assigned to the active group were monitored daily by
telecardiology. No interim visit was scheduled in the active group,
but in case of device dysfunction (technical issue) or health event
(medical issue), the cardiologist investigator was notiﬁed by e-mail,
prompting the rescheduling of the next follow-up visit, if necessary.
It is noteworthy, however, that remote monitoring was not a substi-
tute for emergency medical services. The management of remote FU
was organized in each centre either by direct access of the physician
to the transmitted data or by delegation to an allied professional spe-
ciﬁcally educated to perform this task during ofﬁce hours. No reaction
time was imposed by the protocol, the patients were duly informed
that the physician could only evaluate remote data during ofﬁce
hours and days. The events were assigned a level of warning. Level I
prompted a mandatory interim follow-up to be scheduled as soon
as possible. Level II prompted an optional interim follow-up left to
the physician’s decision (Table 1). Patients assigned to the control
group were managed according to the usual practices of each partici-
pating medical centre, and the follow-up schedule was left to the phy-
sicians’ discretion. So the dates of FU were not imposed by the
protocol but physicians were encouraged to comply with guidelines.
Both patient groups were followed for 18 months. At each follow-up
visit, and at the end of the trial, 18 months after random assignment of
the patient, the investigators interrogated the pacing system and
recorded the possible occurrence of clinical events. We examined
the contributions and reliability of remote monitoring in the early
detection of MAE, and measured the number of contributory follow-
ups, deﬁned as a visit prompting a change in patient management or
reprogramming of the pacemaker. Quality of life was assessed at the
time of enrolment and at the end of the study by means of the
SF-36 questionnaire.
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The patients assigned to the control group were also remotely mon-
itored, though the data were not used for patient surveillance and
were not made available online to the physician investigators. This
allowed a retrospective comparison between the two groups of the
delay between the remote monitoring warning message and subse-
quent medical interventions, such as (i) contributory interim follow-
ups, as deﬁned earlier, or (ii) hospitalizations.
Data collection, management, monitoring,
and analyses
The data were collected at each medical centre on case report forms
completed by the investigators and dedicated staff, under the supervi-
sion of study coordinators and with the assistance of study monitors
assigned by the sponsor. Speciﬁc responsibilities of the study coordina-
tors included (a) the veriﬁcation, along with the study monitors, of the
completeness and accuracy of the case report forms, (b) analysis of the
data in collaboration with the investigators, (c) support of the publica-
tion and presentation of the study results, and (d) preparation of the
adverse event report forms and supporting information for evaluation
by a member of the Safety Monitoring Committee, composed of three
expert cardiologists who did not participate in the trial and were
unaware of the random patient assignment to the active vs. the
control group. The adverse event report forms and supporting docu-
mentation were reviewed by a member of the Safety Monitoring Com-
mittee for conﬁrmation of the investigator’s classiﬁcation of
seriousness and outcome. Discordant classiﬁcations were reviewed
by all members of the committee and ﬁnal classiﬁcations were
reached by consensus. The statistical analyses were performed by a
biostatistician employed by the sponsor.
Statistical analyses
The size of the randomized population was calculated to reach a
.80% power to conﬁrm the non-inferiority of remote monitoring
compared with standard follow-ups, assuming a 7% incidence of
primary study endpoint in both groups and with a non-inferiority
margin of 7%, a 5% signiﬁcance level, and assuming a 10% rate of non-
compliance. The patients were randomly assigned to an active vs. a
control group, in even blocks among study centres. The baseline char-
acteristics of the two study groups were compared by two-sided x
2
test for nominal, qualitative variables, and by Student’s t-test for nor-
mally distributed, quantitative, continuous and discrete variables. The
normal distribution of variables was veriﬁed, using the Kolmogorov–
Smirnov and Shapiro–Wilk tests. Survival free from MAE were esti-
mated by the Kaplan–Meier method and compared, using the
log-rank test. Cox proportional hazard regression analysis was used
to estimate the likelihood of survival, after verifying the proportional
hazard assumption. Cox model was also used to verify the non-
inferiority of remote monitoring vs. primary care in various patient
subgroups. The event rates of each component of the composite
primary study objective were also measured separately. Odds (OR)
and hazard (HR) ratios were calculated and the conﬁdence intervals
(CI) were evaluated with Miettinen’s method. Friedman’s non-
parametric, repeated-measures analysis was used to compare the
SF-36-scale and summary scores. We estimated the number of follow-
ups per patient-year, with 95% CI, in each study group, assuming a
Poisson distribution. A P-value , 0.05 was considered signiﬁcant.
The SPSS statistical software, version 18.0 (SPSS Institute, Inc.,
Chicago, IL, USA) was used for all analyses.
Results
Patient population
Between December 2005 and January 2008, 538 patients (mean
age ¼ 76+9 years, 65% men) were enrolled in the trial, of
whom 269 were assigned to the active and 269 to the control
group. The baseline clinical characteristics of the two study
groups, including antithrombotic regimens, were similar (Table 2).
The proportions of ﬁrst implants (88 vs. 87%) were also similar
in both groups. After 44 patients (8.2%) withdrew their consent
to participate in the study (no compliance with remote monitoring
system or study (n ¼ 40) or patient relocation (n ¼ 4), the ﬁnal
analysis included 494 patients, of whom 248 were assigned to
the active, and 246 to the control group. The mean duration of
follow-up was 18.3+3.3 months.
Analysis of major adverse clinical events
The cumulative, 18-month MAE-free survival of each study group is
shown in Figure 1A. By the end of the trial, 90 patients (18.2%) had
experienced an MAE, including 43 patients (17.3%) in the active
group and 47 (19.1%) in the control group (HR 0.90; 95% CI:
0.59–1.41; P ¼ 0.63), conﬁrming the non-inferiority of remote
monitoring compared with standard care with pre-speciﬁed differ-
ence margin of 7%. That non-inferiority was further conﬁrmed
among selected patient subgroups (Figure 1B).
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18 patients (7.3%) died in the active, vs. 13 (5.3%) in the control
group (P ¼ 0.37). In the active group, 3 patients died from heart
failure and 15 from non-cardiovascular causes, while in the
control group, 4 patients died from strokes and 9 from non-
cardiovascular causes. Hospitalizations for management of
adverse cardiovascular events were recorded in 29 patients in
the active (11.7%) vs. 32 patients in the control (11.8%) group
(P ¼ 0.66). Finally, one patient in the active (0.4%), vs. seven
patients in the control (2.8%) group were hospitalized for
complications related to the pacing system (OR ¼ 0.14; 95% CI:
0.02–0.86; P ¼ 0.03).
The types and numbers of MAE, and the number of patients
who suffered at least one MAE in the overall population and in
each study group, are listed in Table 3. Hospitalizations related
to atrial arrhythmias and strokes were observed in six patients
(six events: four atrial arrhythmias and two strokes) in the
active, vs. 17 patients (18 events: 10 atrial arrhythmias and 8
strokes) in the control group (OR ¼ 0.33; 95% CI: 0.14–0.87;
P ¼ 0.02). All other between-groups differences were statistically
non-signiﬁcant.
Interim follow-ups
The mean number of interim follow-ups per patient-year was
0.51+0.71 (95% CI: 0.43–0.59) in the active group, vs. 1.15+
1.07 (95% CI: 1.03–1.27) in the control group, a 56% difference
(95% CI: 261 to 248; P , 0.001; Figure 2). After the last sched-
uled follow-up, the between-groups difference was 236% (95%
CI 243 to 228; P , 0.001); the mean number of follow-ups per
patient-year was 1.04 + 1.02 (95% CI: 0.94–1.14) in the active
group vs. 1.63 + 1.28 (95% CI: 1.50–1.76) in the control group.
Based on the total number of visits recorded in each group, the
difference became statistically signiﬁcant past the sixth month of
follow-up (Figure 2). On this curve, the 6-month increments of
the control group demonstrate that the patients in the control
group were usually followed every 6 months.
Among 371 interim follow-ups in the control group, 308 (83.0%)
were scheduled visits, 21 (5.7%) were prompted by a patient call, 9
(2.4%) were prompted by a general practitioner’s call, and 33
(8.9%) were scheduled before, during or after a hospitalization.
Among 167 interim follow-up in the active group, 73 (43.7%)
were prompted by remote monitoring, 30 (17.9%) by a patient
call, 21 (12.6%) by a general practitioner’s call, and 43 (25.9%)
were scheduled before, during or after a hospitalization. Out of
73 follow-ups prompted by remote monitoring (i) 34 (47%)
were for clinical events; including 29 (40%) automatic mode
switches and 5 (7%) critical changes in ventricular rate; and
(ii) 39 (53%) were for technical events, including 25 (34%)
changes in capture threshold; 2 (3%) change in lead impedance,
5 (7%) P- or R-wave amplitude safety margin; 7 (9%) transmission
difﬁculties.
In the active group, 126 patients (50.8%) needed no interim
follow-up throughout the 18 months of follow-up.
Contributions of follow-ups
In the control group, 71% of interim follow-ups were non-
contributory vs. 38% in the active group (P , 0.001). Limiting
the analysis to the interim follow-ups prompted by remote moni-
toring, only 26% were non-contributory. At the 18-month sched-
uled follow-ups, 79% were non-contributory in the control vs. 73%
in the active group (P ¼ 0.13).
Detection of major adverse events
Both in the active (24 of 39 events) and in the control (28 of 41
events), the majority of cardiovascular or device-related MAE coin-
cided with emergent hospitalizations. The other 15 events in the
active group were detected by remote monitoring (n ¼ 7) or
during an interim follow-up prompted by a patient’s call or a phys-
ician (n ¼ 7) or at the 18-month follow-up (n ¼ 1). The other 13
events in the control group were detected during an interim
follow-up prompted by a patient’s call or a physician (n ¼ 7) or
during a scheduled follow-up (n ¼ 6). The seven MAE detected
................................................................................
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Table 2 Underlying heart disease, disease
manifestations,and electrocardiographic indications for
pacing in each study group
Active
group
(n 5 269)
Control
group
(n 5 269)
P-value
Underlying heart disease
Primary conduction
system disease
92 (34.2) 80 (29.7) 0.27
Hypertension 71 (26.4) 58 (21.6) 0.19
Cardiomyopathy
Ischaemic 54 (20.0) 55 (20.4) 0.91
Non-ischaemic 15 (5.6) 12 (4.5) 0.55
Valvular heart disease 12 (4.5) 15 (5.6) 0.55
Other 41 (15.2) 56 (20.8) 0.09
None 48 (17.8) 50 (18.6)
Disease manifestations
None 36 (13.4) 22 (8.2) 0.05
Syncope 120 (44.6) 134 (49.8) 0.23
Dyspnoea 55 (20.4) 57 (21.2) 0.83
Lightheadedness 23 (8.5) 26 (9.7) 0.65
Fatigue/weakness 25 (9.3) 29 (10.8) 0.57
Palpitation 19 (7.1) 19 (7.1) 1.00
Others 37 (13.8) 39 (14.5) 0.80
Pacing indications
Sinus node disease 69 (25.6) 73 (27.1) 0.69
Atrioventricular
block
First or second
degree
98 (36.4) 93 (34.6) 0.65
Third degree 79 (29.4) 93 (34.6) 0.20
Bundle branch block 11 (4.1) 4 (1.5) 0.07
Others 12 (4.5) 6 (2.2) 0.15
History of atrial
arrhythmia
26 (9.7) 29 (10.8) 0.67
Antithrombotic therapy 131 (48.7) 133 (49.4) 0.86
Values are numbers (%) of patients in corresponding group.
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tions for atrial arrhythmias (n ¼ 3), heart failure (n ¼ 3), or compli-
cations of valvular heart disease (n ¼ 1).
A retrospective analysis in the control group revealed that 10
events were detectable by remote monitoring including warning
messages for (i) automatic mode switches preceding eight hospita-
lizations for atrial arrhythmias or heart failure, and (ii) less than
safety margin of the P-wave amplitude preceding two hospitaliza-
tions for dislodgement of atrial leads.
Medical interventions delay
The retrospective comparison between the two study groups of
the delay between the remote monitoring warning message and
subsequent medical interventions revealed that 34 interim follow-
ups or hospitalizations were detectable by remote monitoring in
the active group vs. 15 in the control group. Therefore, the
median delay in medical intervention with inter-quartile was 17
(4; 48) days in the active group vs. 139 (33; 201) days in the
control group, representing a mean 117-day gain in the event de-
tection (95% CI: 49–184 days; P ¼ 0.001).
Quality of life
At the time of enrolment in the trial, the mean physical, psycho-
logical, and overall SF-36 quality of life scores in the active group
were 64+22, 68+20, and 68+21, respectively, vs. 64+21,
69+20, and 69+20 in the control group. At last follow-up,
the mean physical, psychological, and overall scores in the active
group were 65+23, 68+21, and 68+22, respectively, vs.
67+20, 71+17, and 71+19 in the control group. These
between- and within-groups differences were all statistically
non-signiﬁcant.
Discussion
In the COMPAS trial, remote monitoring of pacemaker recipients
(i) was as safe as conventional, scheduled follow-ups, (ii) enabled
Figure 1 (A) Cumulative survival free from MAE in each study group estimated by Kaplan–Meier analysis. (B) Outcomes of the test of non-
inferiority among various patient subgroups.
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(iii) decreased signiﬁcantly the number of ambulatory follow-up
visits.
The increasing rate of cardiac device implantations is increasing
the burden of specialized medical centres to a point of becoming
unmanageable. Remote monitoring offers an alternate manage-
ment strategy, which decreases the need for follow-up visits. The
safety and clinical beneﬁts conferred by a systematic application
of this technology needs to be thoroughly validated. While the
TRUST trial conﬁrmed that remote monitoring of ICD recipients
was as safe and effective as standard care,
12 no clinical trial had
examined its performance in permanently paced patients. By its
non-inferiority design, the COMPAS trial conﬁrmed the safety of
remote monitoring in this speciﬁc population. In addition, although
the study was not powered to make these comparisons, signiﬁcant
differences were observed between the two study groups in the
rates of hospitalizations for the management of atrial arrhythmias
and strokes. Several follow-ups prompted by remote monitoring,
which enabled the early detection and management of atrial
arrhythmias in the active group, may have prevented the develop-
ment of more serious adverse events.
13
The a posteriori analysis of all daily transmissions by remote mon-
itoring, including those recorded in the control group, revealed a
considerably longer delay in medical interventions in the control
than in the active group, representing a temporal gain of nearly
120 days. It is noted that in the active group, this delay was left
free to each physician according to the emergency of the
warning message and his knowledge of the patient proﬁle, so the
delay could be more or less prompt. The retrospective analysis
of AWARE, including over 11000 patients from 23 countries,
found similarly that, compared with conventional biannual sched-
uled visits, remote monitoring advanced the detection of adverse
events by a mean of 154 days,
14 a time interval similar to the
144 days observed in COMPAS.
While one might argue with the selection of devices,
15 all
patients enrolled in the COMPAS trial were recipients of dual
chamber pacemakers. The atrial lead, by enabling the detection
of atrial arrhythmias (a function unavailable in single chamber pace-
makers), may have played a role in the added value of remote mon-
itoring. Moreover, for safety reason, the study included only
non-pacemaker-dependent patients, but now it would be interest-
ing to evaluate remote monitoring for patients with spontaneous
ventricular rates ,30 b.p.m.
The majority of adverse events in COMPAS was clinical, and few
technical events, such as lead dysfunction, were observed, probably
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Table 3 Major adverse events in the entire patient
population and in each study group
All
patients,
(n 5 494)
Active
group,
(n 5 248)
Control
group,
(n 5 246)
Deaths
Stroke 4 0 4
Heart failure 3 3 0
Pulmonary disease 3 1 2
Cancer 9 6 3
Other non-cardiac
causes
12 8 4
All deaths 31 18 13
Hospitalizations for cardiovascular adverse events
Ventricular
arrhythmia
2/2 1/1 1/1
Atrial arrhythmia,
stroke
a, or both
24/23 6/6 18/17*
Heart failure 24/19 18/13 6/6
Acute coronary
syndrome
12/11 6/5 6/6
Others 8/8 6/6 2/2
All hospitalizations
for cardiovascular
adverse events
70/61 37/29 33/32
Hospitalizations for device-related adverse events
Infection, extrusion 4/4 0 4/4
Lead dislodgment 2/2 0 2/2
Venous thrombosis 3/2 2/1 1/1
High ventricular
threshold
1/1 0 1/1
All hospitalizations
for device-related
adverse events
10/8 2/1 8/7
All adverse events
b 104/90 54/43 50/47
Values are numbers of adverse events/patients; the comparisons between both
groups for a given type of event were calculated on the ﬁrst event in the case of
multiple events per patient.
aAn ischaemic aetiology of the stroke and history of atrial arrhythmia were
conﬁrmed in all patients.
bSome patients had multiple events in different categories, so the total numbers of
adverse events do no add up.
*P , 0.05.
Figure 2 Number of follow-ups per patient. The blue and
orange curves indicate the number of follow-ups per patient in
the control and the active groups, respectively. The shaded
areas represent the 95% CI. At 18 months, the number of follow-
ups was 36% lower in the active than in the control group. The
slopes (△) of the dotted line indicate the mean number of
visits per year.
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of observation would have allowed the detection of a higher
number of technical adverse events and would have included the
management of the end of pacemaker battery life. The difference
of complications related to the pacing system observed in
COMPAS is difﬁcult to interpret due to the few number of
events. Furthermore, by study design, the total number of follow-
ups over 18 months was 36% lower in the active than in the
control group. Before the ﬁnal 18-month follow-up imposed by
the protocol, the decrease reached nearly 60%. Finally, over 70%
of the routine ambulatory visits in the control group were non-
contributory, whereas the much less frequent and unscheduled
follow-ups prompted by remote monitoring in the active group
were usually medically appropriate.
The results of this trial conﬁrmed that remote monitoring is not
a substitute for an emergency system, as it prompted only a few
hospitalizations. However, it safely eliminated unnecessary follow-
up visits and allowed the early detection of events, prompting
more appropriate follow-up visits. It is noteworthy that over
40% of the overall population transmitted no warning message.
A similar 47% of patients regularly monitored remotely transmit-
ted no warning messages in the AWARE and 40% in the
OEDIPE studies.
5,14 Moreover, over 50% of patients in the active
group needed no interim follow-ups. The observations made in
this trial might soon set a new standard of care for the follow-up
of pacemaker recipients.
The important reduction in FU suggests evaluating economic
implications. The results of this costs analysis will be shown in a
forthcoming publication.
Conclusions
In the COMPAS trial, long-term remote monitoring of pacemaker
recipients was a safe substitute for conventional follow-ups,
decreased the number of ambulatory visits and enabled the early
detection of important clinical and device-related adverse events.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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